BioCentury | Oct 8, 2015
Distillery Therapeutics

Therapeutics: Dengue NS3 protease

...Infectious disease INDICATION: Dengue fever In vitro studies identified a dengue NS3 protease inhibitor that could help treat...
...of N-benzoyl-capped tripeptide analogs and screening in protease activity assays identified a compound that inhibited dengue NS3 protease...
...treatment. Next steps could include testing the compound in animal models of dengue infection. TARGET/MARKER/PATHWAY: Dengue NS3 protease...
BioCentury | Apr 11, 2013
Distillery Therapeutics

Indication: Infectious disease

...in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Dengue fever Dengue NS3 protease...
BioCentury | Feb 21, 2011
Company News

Medivir, J&J deal

...Medivir partnered with Johnson & Johnson's Janssen Pharmaceutica N.V. unit to discover and develop dengue NS3 protease inhibitors...
...N.J. Medivir partnered with Johnson & Johnson's Janssen Pharmaceutica N.V. unit to discover and develop dengue NS3 protease...
BioCentury | Feb 15, 2011
Company News

Medivir, J&J in dengue deal

...Medivir AB (SSE:MVIR B) partnered with Johnson & Johnson (NYSE:JNJ) to discover and develop dengue NS3 protease inhibitors...
Items per page:
1 - 4 of 4